AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23732754
Drug: Interferon beta‐1b,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon beta‐1b, 250 μg, for at least 2 years
Trial: 21097433
Drug: Intravenous parecoxib
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Intravenous parecoxib sodium (40 mg) at anesthesia induction (group A)
Trial: 21097433
Drug: Intravenous parecoxib
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Intravenous parecoxib sodium (40 mg) 30 min before the completion of surgery (group B)
Trial: 17399824
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors and aldosterone antagonists
Trial: 11028492
Drug: Systemic thrombolytic
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic thrombolytic therapy
Trial: 11028492
Drug: High-dose thrombolysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose thrombolysis
Trial: 11028492
Drug: Conventional heparin/anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional heparin/anticoagulation therapy
Trial: 324863
Drug: Aluminum hydroxide
RxNorm normalized name: Aluminum Hydroxide
DrugBank: Aluminum hydroxide (DB06723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminum hydroxide gel (AG) 15 ml
Trial: 324863
Drug: Dummy gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dummy gel (DG)
Trial: 324863
Drug: Aluminum hydroxide
RxNorm normalized name: Aluminum Hydroxide
DrugBank: Aluminum hydroxide (DB06723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminum hydroxide gel (AG)
Trial: 31841818
Drug: Zinc augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc augmentation
Trial: 31488115
Drug: 16-week supervised
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 16-week supervised concurrent (aerobic and strength) exercise intervention program (3 sessions/week, 60 min/session)
Trial: 16425130
Drug: O157-rEPA vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O157-rEPA vaccine (1 or 2 doses)
Trial: 14635316
Drug: Weight reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight reduction treatment
Trial: 9129465
Drug: Fat-free soup
RxNorm normalized name: MALT SOUP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat-free soup with olestra (33.3 g)
Trial: 9129465
Drug: High-fat soup
RxNorm normalized name: MALT SOUP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat soup (33.3 g fat)
Trial: 27676671
Drug: 2.5 mL
RxNorm normalized name: syringe, disposable, 2.5 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mL contrast dye
Trial: 27676671
Drug: 5.0 mL
RxNorm normalized name: ALCOHOL 65.0 mL in 100 mL TOPICAL LIQUID [FRESH DECOR COCONUT CREAM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mL contrast dye
Trial: 23111427
Drug: 1-g vection
RxNorm normalized name: BENZOCAINE 5 g in 100 mL TOPICAL CREAM [Instant Erection]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-g vection responses
Trial: 20193857
Drug: Wrist arthroscopy
RxNorm normalized name: histamine
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Wrist arthroscopy for treatment and evaluation of scaphoid fracture and associated carpal injuries
Trial: 11807347
Drug: Nerve and
RxNorm normalized name: Nerve and muscle antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve and tendon gliding exercises with splint treatment
Trial: 11807347
Drug: Splint treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Splint treatment only
Trial: 1656818
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid 1 g in 500 ml of 5% glucose (Group B)
Trial: 1656818
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml of 5% glucose (Group A)
Trial: 29702118
Drug: Minimal therapist
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal therapist contact Cognitive Behavior Therapy (MC-CBT)
Trial: 29702118
Drug: Standard Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Cognitive Behavior Therapy (S-CBT)
Trial: 26692119
Drug: Tolvaptan (TLV)
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tolvaptan (TLV) plus conventional treatment, n=26
Trial: 26692119
Drug: Furosemide (FRM)
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide (FRM) increased dosage, n=26
Trial: 26692119
Drug: Furosemide (FRM)
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide (FRM) increased dosage
Trial: 25430726
Drug: Mass drug
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass drug administration (MDA) with praziquantel
Trial: 12023696
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (diuretic/beta-blocker)
Trial: 10366118
Drug: Alendronate 5
RxNorm normalized name: ALENDRONATE 5MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 5 mg/day for 2 years followed by 10 mg/day for 12-30 months
Trial: 1784888
Drug: S-ibuprofen (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-ibuprofen (400 mg T.I.D.)
Trial: 1784888
Drug: Racemic ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Racemic ibuprofen (600 mg T.I.D.)
Trial: 7008642
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol powder (0.2 mg/dosis)
Trial: 7008642
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol spray (0.1 mg/dosis)
Trial: 27979034
Drug: Novel oral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel oral anticoagulants (NOAC)
Trial: 25458910
Drug: Azithromycin treatment
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin treatment for 14 days
Trial: 23203904
Drug: Nintendo-Wii Bowling,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintendo-Wii Bowling, 60 min/twice a week for 6 weeks
Trial: 22741442
Drug: Tamoxifen 10
RxNorm normalized name: tamoxifen 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 10 mg bid + VitE 100 mg tid
Trial: 22741442
Drug: Levocarnitine oral
RxNorm normalized name: levocarnitine Oral Wafer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocarnitine oral solution 1 bottle bid + VitE 100 mg tid
Trial: 22741442
Drug: Levocarnitine oral
RxNorm normalized name: levocarnitine Oral Wafer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocarnitine oral solution 1 bottle bid
Trial: 19931288
Drug: Caffeine 250
RxNorm normalized name: caffeine 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 250 mg (paired group)
Trial: 19931288
Drug: Caffeine 250
RxNorm normalized name: caffeine 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 250 mg (Experiment 2)
Trial: 12536346
Drug: Maternal vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal vitamin K2 supplementation (15 mg/d Menatetrenone since the 14th day after parturition)
Trial: 9824933
Drug: Octreotide 0.1
RxNorm normalized name: octreotide 0.1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide 0.1 cc (100 mcg) three times daily subcutaneously for the first seven days post-operatively
Trial: 7988247
Drug: Postoperative combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative combined chemotherapy with cyclophosphamide, doxorubicin, and cisplatin (CAP)
Trial: 3185461
Drug: Caffeine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (400 mg per os)
Trial: 29400626
Drug: Folinic acid
RxNorm normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Folinic acid (5 mg daily for 4 weeks, n=6)
Trial: 26276750
Drug: Soy supplementation
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy supplementation (50 mg isoflavones per day; n = 46)
Trial: 23751235
Drug: Placebo spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo spray with suggestion to increase BP
Trial: 23751235
Drug: Placebo spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo spray with suggestion to decrease BP
Trial: 23751235
Drug: Placebo spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo spray with no suggestion (controls)
Trial: 15932725
Drug: Azathioprine (AzA)
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine (AzA) treatment after conversion from mycophenolate mofetil (MMF), n = 42
Trial: 15932725
Drug: Continued mycophenolate
RxNorm normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continued mycophenolate mofetil (MMF) treatment, n = 45
Trial: 12667396
Drug: Peripancreatic arterial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripancreatic arterial ligation and arterial infusion regional chemotherapy (Group B)
Trial: 12667396
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy after surgery (Group A)
Trial: 1839435
Drug: Amlodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5 mg/day, adjustable to 10 mg/day after 4 weeks)
Trial: 6133287
Drug: Clopenthixol decanoate
RxNorm normalized name: zuclopenthixol decanoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopenthixol decanoate (100 mg 4-weekly to 400 mg 2-weekly)
Trial: 6133287
Drug: Fluphenazine decanoate
RxNorm normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluphenazine decanoate (12.5 mg 4-weekly to 37.5 mg 3-weekly)
Trial: 20117262
Drug: Vaxfectin-adjuvanted monovalent
RxNorm normalized name: Influenza A monovalent (H5N1), ADJUVANTED-2013
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaxfectin-adjuvanted monovalent plasmid DNA vaccine
Trial: 20117262
Drug: Vaxfectin-adjuvanted trivalent
RxNorm normalized name: Influenza, adjuvanted, trivalent, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaxfectin-adjuvanted trivalent plasmid DNA vaccine
Trial: 17585668
Drug: Needling method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needling method for harmonizing spleen-stomach, treated twice each day for 10 days
Trial: 17585668
Drug: Motilium 10
RxNorm normalized name: Motilium 10 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motilium 10 mg, oral administration 3 times each day, 30 min before meals
Trial: 7808491
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus dipyridamole or sulfin-pyrazone
Trial: 30518685
Drug: Low-dose inhaled
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose inhaled carbon monoxide (iCO) at 100 ppm (cohort 1) or 200 ppm (cohort 2) for 90 minutes for up to 5 consecutive days
Trial: 26701762
Drug: Suprascapular nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suprascapular nerve block (SSNB) with physical therapy
Trial: 2654467
Drug: Obsidan (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obsidan (0.1 mg/kg intravenously, then orally for 2-3 days every 3-4 hours, followed by 60-120 mg per 24 hours)
Trial: 24381911
Drug: Submucosal tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Submucosal tramadol (2 mg/kg)
Trial: 24381911
Drug: Isotonic solution
RxNorm normalized name: Isotonic solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic solution (control)
Trial: 19388886
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (basic analgesic regimen of paracetamol and diclofenac)
Trial: 14993578
Drug: Metadate CD
RxNorm normalized name: Metadate CD
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metadate CD (MCD) 20 mg, 40 mg, 60 mg
Trial: 14993578
Drug: Metadate CD
RxNorm normalized name: Metadate CD
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metadate CD (MCD) 40 mg, 60 mg
Trial: 14993578
Drug: Concerta (CON)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concerta (CON) 18 mg, 36 mg, 54 mg
Trial: 9222707
Drug: Sucralfate suspension
RxNorm normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucralfate suspension (2 x 2 g/day)
Trial: 9222707
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional medicine (Control)
Trial: 7897780
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of a nasal decongestant
Trial: 3310717
Drug: Mixed grass
RxNorm normalized name: ALLERGENIC EXTRACT MIXED GRASSES INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed grass pollen allergens from rye grass, timothy grass, cultivated rye and velvet grass (administered daily for 1 year).
Trial: 3310717
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered daily for 1 year).
Trial: 3310717
Drug: Mixed grass
RxNorm normalized name: ALLERGENIC EXTRACT MIXED GRASSES INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed grass pollen allergens (administered daily for 1 year).
Trial: 31529220
Drug: Indigo naturalis
RxNorm normalized name: indigo
DrugBank: Indigo (DB16862)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indigo naturalis (0.5-2.0 g daily)
Trial: 27787540
Drug: Oral voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral voriconazole (loading dose of 400 mg twice daily for 24 hours, followed by 200 mg twice daily for 20 days)
Trial: 22023889
Drug: Pharmacist-physician collaboration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-physician collaboration intervention involving interviews and pharmaceutical care for a year.
Trial: 22023889
Drug: Detection of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detection of adverse drug reactions and drug interactions.
Trial: 22023889
Drug: Detection of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detection of drug interactions.
Trial: 18752586
Drug: Titrated low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Titrated low-dose misoprostol
Trial: 18752586
Drug: Standard induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard induction method (vaginal dinoprostone followed by intravenous oxytocin or intravenous oxytocin alone)
Trial: 15497668
Drug: Lisinopril 20
RxNorm normalized name: lisinopril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 20 mg (Sinopryl)
Trial: 15497668
Drug: Lisinopril/hydrochlorothiazide 20
RxNorm normalized name: lisinopril/hydrochlorothiazide 20 mg-25 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril/hydrochlorothiazide 20 mg/12.5 mg (Sinoretik)
Trial: 11738168
Drug: Single fraction
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single fraction external beam radiation therapy (8 Gy)
Trial: 8179082
Drug: Cefoxitin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (1 g intravenous every 8 hours starting at induction, three times)
Trial: 31642930
Drug: Signs changed
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Signs changed weekly
Trial: 31642930
Drug: Signs changed
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Signs changed monthly
Trial: 30420367
Drug: Patellar mobilization
RxNorm normalized name: Oxtellar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patellar mobilization therapy (PMT)
Trial: 27509602
Drug: Meloxicam, 7.5
RxNorm normalized name: Meloxicam, 7.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam, 7.5 mg, once a day for 6 weeks.
Trial: 17321111
Drug: Risperidone 4
RxNorm normalized name: risperidone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 4 mg/day for 6 weeks
Trial: 11372795
Drug: 17 g
RxNorm normalized name: lancets 17 gauge MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 g of PEG daily for 4 days
Trial: 11372795
Drug: PEG treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG treatment
Trial: 16306137
Drug: PEG therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG therapy
Trial: 11372795
Drug: PEG laxative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG laxative
Trial: 31066646
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose regimen containing voclosporin, MMF and steroid therapy
Trial: 31066646
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care treatment with high dose MMF and steroids
Trial: 16517764
Drug: G-CSF therapy
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF therapy (subcutaneous injections of 15 microg/kg per day for 5 days)
Trial: 27819485
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (Ω3 + PEP)
Trial: 27819485
Drug: Omega-3 (Ω3)
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 (Ω3) monotherapy
Trial: 27454370
Drug: Family systems
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family systems therapy
Trial: 25060157
Drug: Yoghurt enriched
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yoghurt enriched with 2 g of plant stanol ester (PS group)
Trial: 18990996
Drug: Immediate nonocclusal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate nonocclusal loading of dental implants
Trial: 18990996
Drug: Early nonocclusal
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early nonocclusal loading of dental implants (6 weeks)
Trial: 7104143
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg pindolol three times daily for 2 days
Trial: 7104143
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg propranolol three times daily for 2 days
Trial: 26853339
Drug: Gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine plus Radiation Therapy (RT) at a recommended phase 2 dose of 750 mg/m(2)/wk during the last 4 weeks of RT
Trial: 26853339
Drug: Gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine plus Radiation Therapy (RT)
Trial: 24408514
Drug: Topical Cyperus
RxNorm normalized name: Cyperus rotundus whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Cyperus rotundus oil
Trial: 23022970
Drug: Colchicine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (1.0 mg twice daily for the first day followed by 0.5 mg twice daily for 1 month in patients ≥70 kg; halved doses for patients <70 kg or intolerant)
Trial: 10193294
Drug: Milrinone 50
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Milrinone 50 micrograms kg‐1 administered at the end of bypass
Trial: 17569583
Drug: Sodium phosphate
RxNorm normalized name: Sodium Phosphate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium phosphate (SP) loading (1g of tribasic dodecahydrate sodium phosphate, four times daily for 6 days)
Trial: 16958396
Drug: Protocol of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol of 150 ml of 300 mg I/ml
Trial: 16958396
Drug: Protocol of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol of 100 ml of 300 mg I/ml
Trial: 16958396
Drug: Protocol of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol of 100 ml of 350 mg I/ml
Trial: 11129986
Drug: Neoadjuvant tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant tamoxifen (20 mg/day for 3 weeks)
Trial: 9065902
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist treatment (triptorelin) for 6 months
Trial: 1640278
Drug: Heparin (1/2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (1/2 unit per milliliter of continuous intravenous infusate or intermittent heparin flush)
Trial: 29798783
Drug: Matched warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched warfarin group